{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:27:01Z","timestamp":1777951621843,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The IPF-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc. and run in collaboration with the Duke Clinical Research Institute and enrolling centers."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03641-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:44:42Z","timestamp":1774424682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Aparna C","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan L","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Belperio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina M","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie L","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"3641_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655\u201365.","journal-title":"JAMA"},{"key":"3641_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12931-023-02503-5","volume":"24","author":"ML Neely","year":"2023","unstructured":"Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, et al. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023;24:209.","journal-title":"Respir Res"},{"key":"3641_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00408-025-00789-4","volume":"203","author":"E Cocconcelli","year":"2025","unstructured":"Cocconcelli E, Bernardinello N, Cameli P, Di Liberti R, Alhamad EH, Gregori D, et al. Prevalence and predictors of response to antifibrotics in long-term survivors with idiopathic pulmonary fibrosis. Lung. 2025;203:35.","journal-title":"Lung"},{"key":"3641_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","volume":"5","author":"JD Herazo-Maya","year":"2017","unstructured":"Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med. 2017;5:857\u201368.","journal-title":"Lancet Respir Med"},{"key":"3641_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5:946\u201355.","journal-title":"Lancet Respir Med"},{"key":"3641_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.chest.2020.04.066","volume":"158","author":"A Adegunsoye","year":"2020","unstructured":"Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, et al. Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis. Chest. 2020;158:1526\u201334.","journal-title":"Chest"},{"key":"3641_CR7","doi-asserted-by":"publisher","first-page":"12049","DOI":"10.1038\/s41598-020-67956-w","volume":"10","author":"KC Norman","year":"2020","unstructured":"Norman KC, O\u2019Dwyer DN, Salisbury ML, DiLillo KM, Lama VN, Xia M, et al. Identification of a unique temporal signature in blood and BAL associated with IPF progression. Sci Rep. 2020;10:12049.","journal-title":"Sci Rep"},{"key":"3641_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00408-021-00505-y","volume":"200","author":"JL Todd","year":"2022","unstructured":"Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, et al. Association of circulating proteins with death or lung transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry cohort. Lung. 2022;200:11\u20138.","journal-title":"Lung"},{"key":"3641_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","volume":"209","author":"JM Oldham","year":"2024","unstructured":"Oldham JM, Huang Y, Bose S, Ma SF, Kim JS, Schwab A, et al. Proteomic biomarkers of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2024;209:1111\u201320.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.4049\/jimmunol.175.3.1894","volume":"175","author":"E Addis-Lieser","year":"2005","unstructured":"Addis-Lieser E, K\u00f6hl J, Chiaramonte MG. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol. 2005;175:1894\u2013902.","journal-title":"J Immunol"},{"key":"3641_CR11","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1096\/fj.13-247650","volume":"28","author":"H Gu","year":"2014","unstructured":"Gu H, Mickler EA, Cummings OW, Sandusky GE, Weber DJ, Gracon A, et al. Crosstalk between TGF-\u03b21 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J. 2014;28:4223\u201334.","journal-title":"FASEB J"},{"key":"3641_CR12","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1096\/fj.201500044","volume":"30","author":"H Gu","year":"2016","unstructured":"Gu H, Fisher AJ, Mickler EA, Duerson F 3rd, Cummings OW, Peters-Golden M, et al. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. FASEB J. 2016;30:2336\u201350.","journal-title":"FASEB J"},{"key":"3641_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21767\/2573-5365.100037","volume":"3","author":"AJ Fisher","year":"2017","unstructured":"Fisher AJ, Cipolla E, Varre A, Gu H, Mickler EA, Vittal R. Potential mechanisms underlying TGF-\u03b2-mediated complement activation in lung fibrosis. Cell Mol Med Open Access. 2017;3:14.","journal-title":"Cell Mol Med Open Access"},{"key":"3641_CR14","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1152\/ajplung.00395.2017","volume":"315","author":"T Okamoto","year":"2018","unstructured":"Okamoto T, Mathai SK, Hennessy CE, ancock LA, Walts AD, Stefanski AL, et al. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018;315:L1\u201310.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3641_CR15","doi-asserted-by":"publisher","first-page":"151220","DOI":"10.1016\/j.bbrc.2024.151220","volume":"745","author":"D Ma","year":"2025","unstructured":"Ma D, Hua Y, Lu Y. Complement factor H drives idiopathic pulmonary fibrosis by autocrine C3 regulation, suppressing macrophage phagocytosis and enhancing fibrotic progression. Biochem Biophys Res Commun. 2025;745:151220.","journal-title":"Biochem Biophys Res Commun"},{"key":"3641_CR16","doi-asserted-by":"publisher","first-page":"46560","DOI":"10.1038\/srep46560","volume":"7","author":"DN O\u2019Dwyer","year":"2017","unstructured":"O\u2019Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, et al. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci Rep. 2017;7:46560.","journal-title":"Sci Rep"},{"key":"3641_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1165\/rcmb.2021-0463OC","volume":"67","author":"R Vittal","year":"2022","unstructured":"Vittal R, Fisher AJ, Thompson EL, Cipolla EM, Gu H, Mickler EA, et al. Overexpression of decay accelerating factor mitigates fibrotic responses to lung injury. Am J Respir Cell Mol Biol. 2022;67:459\u201370.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3641_CR18","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.12659\/MSM.908702","volume":"24","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xin Q, Wu Z, Wang C, Wang Y, Wu Q, et al. Application of isobaric tags for relative and absolute quantification (iTRAQ) coupled with two-dimensional liquid chromatography\/tandem mass spectrometry in quantitative proteomic analysis for discovery of serum biomarkers for idiopathic pulmonary fibrosis. Med Sci Monit. 2018;24:4146\u201353.","journal-title":"Med Sci Monit"},{"key":"3641_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12931-019-1190-z","volume":"20","author":"JL Todd","year":"2019","unstructured":"Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, et al. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019;20:227.","journal-title":"Respir Res"},{"key":"3641_CR20","doi-asserted-by":"publisher","first-page":"e12871","DOI":"10.15252\/emmm.202012871","volume":"13","author":"CH Mayr","year":"2021","unstructured":"Mayr CH, Simon LM, Leuschner G, Ansari M, Schniering J, Geyer PE, et al. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Mol Med. 2021;13:e12871.","journal-title":"EMBO Mol Med"},{"key":"3641_CR21","doi-asserted-by":"publisher","first-page":"1236495","DOI":"10.3389\/fmed.2023.1236495","volume":"10","author":"LIB Sikkeland","year":"2023","unstructured":"Sikkeland LIB, Ueland T, Lund MB, Durheim MT, Mollnes TE. A role for the terminal C5-C9 complement pathway in idiopathic pulmonary fibrosis. Front Med (Lausanne). 2023;10:1236495.","journal-title":"Front Med (Lausanne)"},{"key":"3641_CR22","doi-asserted-by":"publisher","first-page":"e000108","DOI":"10.1136\/bmjresp-2015-000108","volume":"3","author":"EC O\u2019Brien","year":"2016","unstructured":"O\u2019Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) Registry. BMJ Open Respir Res. 2016;3:e000108.","journal-title":"BMJ Open Respir Res"},{"key":"3641_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-023-02435-0","volume":"24","author":"P Ruan","year":"2023","unstructured":"Ruan P, Todd JL, Zhao H, iu Y, Vinisko R, Soellner JF, et al. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023;24:141.","journal-title":"Respir Res"},{"key":"3641_CR25","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/ijc.31896","volume":"144","author":"D Qian","year":"2019","unstructured":"Qian D, Liu H, Wang X, Ge J, Luo S, Patz EF Jr, et al. Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer. 2019;144:1867\u201376.","journal-title":"Int J Cancer"},{"key":"3641_CR26","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","volume":"26","author":"V Ramlall","year":"2020","unstructured":"Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26:1609\u201315.","journal-title":"Nat Med"},{"key":"3641_CR27","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R25.","journal-title":"Genome Biol"},{"key":"3641_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1164\/rccm.2111053","volume":"167","author":"AU Wells","year":"2003","unstructured":"Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"3641_CR30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684\u201391.","journal-title":"Ann Intern Med"},{"key":"3641_CR31","unstructured":"ILD Immune Cell Atlas. http:\/\/ildimmunecellatlas.com\/. Accessed 7 November 2024."},{"key":"3641_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cei.12952","volume":"188","author":"R Lubbers","year":"2017","unstructured":"Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188:183\u201394.","journal-title":"Clin Exp Immunol"},{"key":"3641_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1164\/rccm.202306-0979OC","volume":"210","author":"A Unterman","year":"2024","unstructured":"Unterman A, Zhao AY, Neumark N, Schupp JC, Ahangari F, Cosme C Jr, et al. Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2024;210:484\u201396.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR34","doi-asserted-by":"publisher","first-page":"e0159878","DOI":"10.1371\/journal.pone.0159878","volume":"11","author":"SL Ashley","year":"2016","unstructured":"Ashley SL, Xia M, Murray S, O\u2019Dwyer DN, Grant E, White ES, et al. Six-SOMAmer index relating to immune, protease and angiogenic functions predicts progression in IPF. PLoS ONE. 2016;11:e0159878.","journal-title":"PLoS ONE"},{"key":"3641_CR35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","volume":"190","author":"PL Molyneaux","year":"2014","unstructured":"Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906\u201313.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1164\/rccm.201809-1650OC","volume":"199","author":"DN O\u2019Dwyer","year":"2019","unstructured":"O\u2019Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med. 2019;199:1127\u201338.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR37","doi-asserted-by":"publisher","first-page":"1901519","DOI":"10.1183\/13993003.01519-2019","volume":"55","author":"R Invernizzi","year":"2020","unstructured":"Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, et al. Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. Eur Respir J. 2020;55:1901519.","journal-title":"Eur Respir J"},{"key":"3641_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12931-023-02657-2","volume":"25","author":"MG Detsika","year":"2024","unstructured":"Detsika MG, Palamaris K, Dimopoulou I, Kotanidou A, Orfanos SE. The complement cascade in lung injury and disease. Respir Res. 2024;25:20.","journal-title":"Respir Res"},{"key":"3641_CR39","doi-asserted-by":"crossref","unstructured":"Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009:729\u201340.","DOI":"10.1038\/nri2620"},{"key":"3641_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0016-5085(96)70058-6","volume":"111","author":"A Andoh","year":"1996","unstructured":"Andoh A, Fujiyama Y, Sumiyoshi K, Sakumoto H, Bamba T. Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology. 1996;111:911\u20138.","journal-title":"Gastroenterology"},{"key":"3641_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/03009749409099280","volume":"23","author":"ME Davies","year":"1994","unstructured":"Davies ME, Horner A, Loveland BE, McKenzie IF. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand J Rheumatol. 1994;23:316\u201321.","journal-title":"Scand J Rheumatol"},{"key":"3641_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1365-2249.1998.00660.x","volume":"113","author":"J Nasu","year":"1998","unstructured":"Nasu J, Mizuno M, Uesu T, Takeuchi K, Inaba T, Ohya S, et al. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol. 1998;113:379\u201385.","journal-title":"Clin Exp Immunol"},{"key":"3641_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2011-04-348474","volume":"118","author":"C Fang","year":"2011","unstructured":"Fang C, Miwa T, Song WC. Decay-accelerating factor regulates T-cell immunity in the context of inflammation by influencing costimulatory molecule expression on antigen-presenting cells. Blood. 2011;118:100\u20131014.","journal-title":"Blood"},{"key":"3641_CR44","doi-asserted-by":"publisher","first-page":"205ra136","DOI":"10.1126\/scitranslmed.3005964","volume":"5","author":"JD Herazo-Maya","year":"2013","unstructured":"Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136.","journal-title":"Sci Transl Med"},{"key":"3641_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1164\/rccm.202008-3093OC","volume":"204","author":"Y Huang","year":"2021","unstructured":"Huang Y, Oldham JM, Ma SF, Unterman A, Liao SY, Barros AJ, et al. Blood transcriptomics predicts progression of pulmonary fibrosis and associated natural killer cells. Am J Respir Crit Care Med. 2021;204:197\u2013208.","journal-title":"Am J Respir Crit Care Med"},{"key":"3641_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00408-024-00742-x","volume":"202","author":"JF S\u00f6llner","year":"2024","unstructured":"S\u00f6llner JF, Bentink S, Hesslinger C, Leonard TB, Neely ML, Patel NM, et al. Utility of the 52-gene risk score to identify patients with idiopathic pulmonary fibrosis at greater risk of mortality in the era of antifibrotic therapy. Lung. 2024;202:595\u20139.","journal-title":"Lung"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03641-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:02:09Z","timestamp":1777888929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3641"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03641-2","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and\/or local Independent Ethics Committees prior to enrollment at each site (see Acknowledgments). Ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for these analyses. The study was carried out in compliance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice of the International Conference on Harmonization. All patients provided written informed consent. The IPF-PRO Registry was registered with ClinicalTrials.gov (Identifier: NCT01915511).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ACS, MLN, SMP and JLT are faculty members, and HM is a staff member, at the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. to coordinate the IPF-PRO\/ILD-PRO Registry. JLT also reports grants from AstraZeneca, Boehringer Ingelheim, CareDx and has participated on Data Safety Monitoring Boards or Advisory Boards for Altavant, Avalyn, Natera, Sanofi, Theravance. SMP also reports research funding to Duke University\/Duke Clinical Research Institute from Bristol Myers Squibb; royalties or licenses from UpToDate; and consulting fees from Bristol Myers Squibb, Mallinckrodt, Sanofi. RS and NMP are employees of Boehringer Ingelheim. JAB is a site investigator for the IPF-PRO\/ILD-PRO Registry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}